Logo image of INO

INOVIO PHARMACEUTICALS INC (INO) Stock Fundamental Analysis

NASDAQ:INO - Nasdaq - US45773H4092 - Common Stock

2.2  +0.12 (+5.77%)

Premarket: 2.15 -0.05 (-2.27%)

Fundamental Rating

2

INO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. INO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INO is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INO has reported negative net income.
INO had a negative operating cash flow in the past year.
In the past 5 years INO always reported negative net income.
In the past 5 years INO always reported negative operating cash flow.
INO Yearly Net Income VS EBIT VS OCF VS FCFINO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

With a Return On Assets value of -105.43%, INO is not doing good in the industry: 77.35% of the companies in the same industry are doing better.
With a Return On Equity value of -153.49%, INO is not doing good in the industry: 64.78% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -105.43%
ROE -153.49%
ROIC N/A
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.65%
ROE(5y)-765.57%
ROIC(3y)N/A
ROIC(5y)N/A
INO Yearly ROA, ROE, ROICINO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for INO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INO Yearly Profit, Operating, Gross MarginsINO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -5K -10K -15K

More info and screens

5

2. Health

2.1 Basic Checks

INO does not have a ROIC to compare to the WACC, probably because it is not profitable.
INO has more shares outstanding than it did 1 year ago.
INO has more shares outstanding than it did 5 years ago.
The debt/assets ratio for INO is higher compared to a year ago.
INO Yearly Shares OutstandingINO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M 20M
INO Yearly Total Debt VS Total AssetsINO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

2.2 Solvency

INO has an Altman-Z score of -23.87. This is a bad value and indicates that INO is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INO (-23.87) is worse than 88.85% of its industry peers.
There is no outstanding debt for INO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.87
ROIC/WACCN/A
WACC10.95%
INO Yearly LT Debt VS Equity VS FCFINO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

A Current Ratio of 3.88 indicates that INO has no problem at all paying its short term obligations.
INO has a Current ratio (3.88) which is in line with its industry peers.
A Quick Ratio of 3.88 indicates that INO has no problem at all paying its short term obligations.
INO has a Quick ratio (3.88) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.88
Quick Ratio 3.88
INO Yearly Current Assets VS Current LiabilitesINO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

INO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 40.34%, which is quite impressive.
Looking at the last year, INO shows a very negative growth in Revenue. The Revenue has decreased by -76.14% in the last year.
The Revenue for INO have been decreasing by -51.34% on average. This is quite bad
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.95%
Revenue 1Y (TTM)-76.14%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.34%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, INO will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.55% on average per year.
INO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 166.24% yearly.
EPS Next Y29.04%
EPS Next 2Y21.53%
EPS Next 3Y18.37%
EPS Next 5Y13.55%
Revenue Next Year-87.71%
Revenue Next 2Y71.39%
Revenue Next 3Y194.58%
Revenue Next 5Y166.24%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INO Yearly Revenue VS EstimatesINO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 100M 200M 300M
INO Yearly EPS VS EstimatesINO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INO Price Earnings VS Forward Price EarningsINO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INO Per share dataINO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

A more expensive valuation may be justified as INO's earnings are expected to grow with 18.37% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.53%
EPS Next 3Y18.37%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INOVIO PHARMACEUTICALS INC

NASDAQ:INO (1/21/2025, 8:07:44 PM)

Premarket: 2.15 -0.05 (-2.27%)

2.2

+0.12 (+5.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Inst Owners31.64%
Inst Owner Change0.35%
Ins Owners0.81%
Ins Owner Change0%
Market Cap79.31M
Analysts78
Price Target10.88 (394.55%)
Short Float %12.11%
Short Ratio4.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.23%
Min EPS beat(2)-6.95%
Max EPS beat(2)23.41%
EPS beat(4)2
Avg EPS beat(4)-0.07%
Min EPS beat(4)-29.26%
Max EPS beat(4)23.41%
EPS beat(8)3
Avg EPS beat(8)-2.96%
EPS beat(12)4
Avg EPS beat(12)-6.59%
EPS beat(16)6
Avg EPS beat(16)-8.25%
Revenue beat(2)0
Avg Revenue beat(2)-58.95%
Min Revenue beat(2)-100%
Max Revenue beat(2)-17.89%
Revenue beat(4)0
Avg Revenue beat(4)-72.09%
Min Revenue beat(4)-100%
Max Revenue beat(4)-17.89%
Revenue beat(8)1
Avg Revenue beat(8)-24.54%
Revenue beat(12)3
Avg Revenue beat(12)88.81%
Revenue beat(16)4
Avg Revenue beat(16)78.61%
PT rev (1m)0%
PT rev (3m)-36.32%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.68%
EPS NY rev (1m)0%
EPS NY rev (3m)6.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-84.15%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-60.02%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 389.23
P/FCF N/A
P/OCF N/A
P/B 1.08
P/tB 1.08
EV/EBITDA N/A
EPS(TTM)-4.51
EYN/A
EPS(NY)-3.22
Fwd EYN/A
FCF(TTM)-3.08
FCFYN/A
OCF(TTM)-3.07
OCFYN/A
SpS0.01
BVpS2.04
TBVpS2.04
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.43%
ROE -153.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-73.52%
ROA(5y)-66.86%
ROE(3y)-105.65%
ROE(5y)-765.57%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.61%
Cap/Sales 239.41%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.88
Quick Ratio 3.88
Altman-Z -23.87
F-Score2
WACC10.95%
ROIC/WACCN/A
Cap/Depr(3y)23.17%
Cap/Depr(5y)26.62%
Cap/Sales(3y)39.12%
Cap/Sales(5y)32.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.95%
EPS Next Y29.04%
EPS Next 2Y21.53%
EPS Next 3Y18.37%
EPS Next 5Y13.55%
Revenue 1Y (TTM)-76.14%
Revenue growth 3Y-51.76%
Revenue growth 5Y-51.34%
Sales Q2Q%-100%
Revenue Next Year-87.71%
Revenue Next 2Y71.39%
Revenue Next 3Y194.58%
Revenue Next 5Y166.24%
EBIT growth 1Y25.35%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-26.49%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y49.28%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y49.17%
OCF growth 3YN/A
OCF growth 5YN/A